AIM

← Markets

AIMAIM ImmunoTech Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Thu, Aug 27
8:01 AMglobenewswire.comAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
Wed, Aug 12
7:44 AMYahooAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
Mon, Aug 3
7:33 AMYahooAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
Fri, Jul 24
7:04 AMYahooZacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
Tue, Jul 7
8:03 AMYahooAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
Wed, Jun 24
7:29 AMYahooAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
Mon, Jun 22
7:45 AMYahooAIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Thu, Jun 18
8:01 AMYahooAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
Mon, Jun 15
7:01 AMYahooAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Tue, Jun 9
8:29 AMYahooAIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
Mon, Jun 8
7:33 AMYahooAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Thu, Jun 4
7:55 AMYahooAIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness